| 產(chǎn)品編號 | bs-20601R-Cy3 |
| 英文名稱1 | Rabbit Anti-iNos/Nos-2/Cy3 Conjugated antibody |
| 中文名稱 | Cy3標記的一氧化氮合成酶-2（誘導型）抗體 |
| 別 名 | i NOS; Nitric Oxide Synthase, Inducible; HEP NOS; Hepatocyte NOS; HEPNOS; Inducible nitric oxide synthase; Inducible NO synthase; Inducible NOS; INOS; Inosl; MAC NOS; Macrophage NOS; Nitric oxide synthase 2 inducible macrophage; Nitric oxide synthase 2A (inducible hepatocytes); Nitric oxide synthase inducible; NOS 2; NOS 2A; NOS; Nos II; NOS type II; Nos2; NOS2A; NOS2_HUMAN. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 細胞生物 免疫學 神經(jīng)生物學 信號轉導 轉錄調節(jié)因子 激酶和磷酸酶 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human, Mouse, (predicted: Rat, Dog, Pig, Horse, Sheep, ) |
| 產(chǎn)品應用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 130kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human iNos/Nos-2 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Nitric oxide (NO) is an inorganic, gaseous free radical that carries a variety of messages between cells. Vasorelaxation, neurotransmission and cytotoxicity can all be potentiated through cellular response to NO. NO production is mediated by members of the nitric oxide synthase (NOS) family. NOS catalyzes the oxidization of L-arginine to produce L-citrulline and NO. Two constitutive isoforms, brain or neuronal NOS (b or nNOS, type I) & endothelial cell NOS (eNOS, type III), and one inducible isoform (iNOS, type II), have been cloned. All NOS isoforms contain calmodulin, nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), and flavin mononucleotide (FMN) binding domains. Nitric oxide synthase is expressed in liver, macrophages, hepatocytes, synoviocytes, stimulated glial cells and smooth muscle cells. Cytokines such as interferon-gamma (IFN), tumor necrosis factor (TNF), interleukin-1 and -2, and lipopolysaccarides (LPS) cause an increase in iNOS mRNA, protein, and activity levels. Protein kinase C-stimulating agents exhibit the same effect on iNOS activity. After cytokine induction, iNOS exhibits a delayed activity response which is then followed by a significant increase in NO production over a long period of time. Human iNOS is regulated by calcium/calmodulin (in contrast with mouse NOS2). Function: Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such COX2. Subunit: Homodimer. Binds SLC9A3R1. Tissue Specificity: Expressed in the liver, retina, bone cells and airway epithelial cells of the lung. Not expressed in the platelets. Similarity: Belongs to the NOS family. Contains 1 FAD-binding FR-type domain. Contains 1 flavodoxin-like domain. Database links: Entrez Gene: 4843?Human Entrez Gene: 18126?Mouse Omim: 163730?Human SwissProt: P35228?Human SwissProt: P29477?Mouse Unigene: 709191?Human Unigene: 2893?Mouse Unigene: 10400?Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 合成與降解（Synthesis and Degradation） 催化生物體內一氧化氮（NO）生成的酶。分神經(jīng)型一氧化氮合成的酶（nNOS or NOS-1）、誘導型一氧化氮合成的酶（iNOS or NOS-2）、內皮型一氧化氮合成的酶（eNOS or NOS-3）。 |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
